[Lung cancer].
The main purpose of tumor classification is to distinguish clear differences such as deciding treatment or showing a peculiar characteristic. In the treatment of lung cancer, the standard for treatment selection is to make the important classification of small cell lung cancer(SCLC)and non-small cell lung cancer(NSCLC). This is based on the fact that with a clinical-pathology difference and treatment reactivity, the prognosis differs between SCLC and NSCLC. In the 21st century, it has become insufficient to choose a treatment only by the classification of NSCLC with the advent of gefitinib a molecular target drug. Thus, treatment must be chosen in terms of the presence or absence of adenocarcinoma, an ethnic group, gender, a smoking history, and also the gene mutation. Moreover, it was reported by ASCO in 2008 that efficacy of pemetrexed is low for non-squamous cell carcinoma. From now on, not the NSCLC classification, but further detailed classification is needed to choose a treatment. Treatment selection in terms of the individual will be possible with ongoing study.
Mizutani
Hideaki
H
Dept. of Respiratory Medicine, Nippon Medical School, Tokyo, Japan.
Gemma
Akihiko
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000145:classification* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis
D000970:Antineoplastic Agents